0001683168-24-003004.txt : 20240506 0001683168-24-003004.hdr.sgml : 20240506 20240506121414 ACCESSION NUMBER: 0001683168-24-003004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240503 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240506 DATE AS OF CHANGE: 20240506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41282 FILM NUMBER: 24916526 BUSINESS ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 332-216-1147 MAIL ADDRESS: STREET 1: 1177 AVENUE OF THE AMERICAS STREET 2: 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 8-K 1 sunshine_8k.htm FORM 8-K 8-K
false 0001402328 0001402328 2024-05-03 2024-05-03 0001402328 us-gaap:CommonStockMember 2024-05-03 2024-05-03 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2024-05-03 2024-05-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 3, 2024

 

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Colorado 001-41282 20-5566275

(State or other jurisdiction

of incorporation)

 (Commission File Number) (IRS Employer ID No.)

 

1177 Avenue of the Americas, 5th Floor

New York , NY 10036

(Address of principal executive offices) (zip code)

 

(332) 216-1147

(Registrant’s telephone number, including area code)

 

________________________________________

(Former name or former address, if changed since last report.)

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Common Stock Purchase Warrants SBFMW The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Section 4 – Matters Related to Accountants and Financial Statements

 

Item 4.01 Changes in Registrant’s Certifying Accountant

 

(a)       The financial statements of Sunshine Biopharma, Inc. (the “Company”), for the fiscal years ended December 31, 2023 and 2022, were audited by BF Borgers CPA, PC (“Borgers”). On May 3, 2024, the Securities and Exchange Commission (the “SEC”) announced that it had settled charges against Borgers that it failed to conduct audits in accordance with the standards of the Public Company Accounting Oversight Board (the “PCAOB”). As part of the settlement, Borgers agreed to a permanent ban on appearing or practicing before the SEC. As a result of Borgers’ settlement with the SEC, the Company has dismissed Borgers as its independent accountant. The decision to dismiss Borgers as the Company’s independent registered public accounting firm was approved by the audit committee of the Company’s board of directors.

 

Borgers’ reports on the Company’s financial statements for the two most recent fiscal years did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope, or accounting principles.

 

During the Company’s two most recent fiscal years ended December 31, 2023 and 2022 and the subsequent interim period through May 3, 2024, there were no disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K, with Borgers on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Borgers, would have caused it to make reference to the subject matter of the disagreements in connection with its reports. Also during this same period, there were no reportable events that existed within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto.

 

The Company provided Borgers with the disclosures under this Item 4.01(a), and requested Borgers to furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company in this Item 4.01(a) and, if not, stating the respects in which it does not agree. Borgers’ letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.

  

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
16.1  

Letter from Borgers

104   Cover Page Interactive Data File (formatted in Inline XBRL).

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 6, 2024 SUNSHINE BIOPHARMA, INC.
   
   
  By: /s/ Dr. Steve N. Slilaty                                           
  Dr. Steve N. Slilaty, Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
 EX-16.1 2 sunshine_ex1601.htm LETTER FROM BORGERS

Exhibit 16.1

 

 

 

 

May 6, 2024

 

United States Securities and Exchange Commission

Office of the Chief Accountant

100 F Street, N.E.

Washington, D.C. 20549

 

 

 

Re: Sunshine Biopharma, Inc.

 

Ladies and Gentleman:

 

We have read the statements under item 4.01 in the Form 8-K dated May 6, 2024, of Sunshine Biopharma, Inc. (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to our firm. We have no basis to, and therefore, do not agree or disagree with the other statements made by the Company in the Form 8-K.

 

 

Sincerely,

 

 

 

 

BF Borgers CPA PC

Certified Public Accountants

Lakewood, CO

 GRAPHIC 3 image_004.jpg GRAPHIC begin 644 image_004.jpg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end GRAPHIC 4 image_006.jpg GRAPHIC begin 644 image_006.jpg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sbfm-20240503.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 sbfm-20240503_def.xml XBRL DEFINITION FILE EX-101.LAB 7 sbfm-20240503_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Common Stock Purchase Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 sbfm-20240503_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
May 03, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date May 03, 2024
Entity File Number 001-41282
Entity Registrant Name SUNSHINE BIOPHARMA, INC.
Entity Central Index Key 0001402328
Entity Tax Identification Number 20-5566275
Entity Incorporation, State or Country Code CO
Entity Address, Address Line One 1177 Avenue of the Americas,
Entity Address, Address Line Two 5th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10036
City Area Code (332)
Local Phone Number 216-1147
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol SBFM
Security Exchange Name NASDAQ
Common Stock Purchase Warrants [Member]  
Title of 12(b) Security Common Stock Purchase Warrants
Trading Symbol SBFMW
Security Exchange Name NASDAQ
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sbfm-20240503.xsd sbfm-20240503_def.xml sbfm-20240503_lab.xml sbfm-20240503_pre.xml sunshine_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sunshine_8k.htm": { "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20240503", "dts": { "schema": { "local": [ "sbfm-20240503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "sbfm-20240503_def.xml" ] }, "labelLink": { "local": [ "sbfm-20240503_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20240503_pre.xml" ] }, "inline": { "local": [ "sunshine_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://sunshinebiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "SBFM_CommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20240503", "localname": "CommonStockPurchaseWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 18 0001683168-24-003004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-003004-xbrl.zip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sunshine_8k_htm.xml IDEA: XBRL DOCUMENT 0001402328 2024-05-03 2024-05-03 0001402328 us-gaap:CommonStockMember 2024-05-03 2024-05-03 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2024-05-03 2024-05-03 iso4217:USD shares iso4217:USD shares false 0001402328 8-K 2024-05-03 SUNSHINE BIOPHARMA, INC. CO 001-41282 20-5566275 1177 Avenue of the Americas, 5th Floor New York NY 10036 (332) 216-1147 Common Stock, par value $0.001 SBFM NASDAQ Common Stock Purchase Warrants SBFMW NASDAQ false false false false false